Bibliographic Info
GuidelineWHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment
Year of Publication2020
Issuing InstitutionWorld Health Organization
Recommendation
Status
Maintained
Recommended in favor
Conditional
Certainty of evidence
Very low
In patients with confirmed rifampicin-susceptible and isoniazid-resistant tuberculosis, treatment with rifampicin, ethambutol, pyrazinamide and levofloxacin is recommended for a duration of 6 months
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis
Year2018
InstitutionWorld Health Organization
Guideline
WHO consolidated guidelines on drug-resistant tuberculosis treatment
Year2019
InstitutionWorld Health Organization
Guideline
WHO consolidated guidelines on tuberculosis: module 4: treatment and care
Year2025
InstitutionWorld Health Organization